Sangamo BioSciences | SGMO - Current Liabilities


Sangamo BioSciences reported $47.66M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Alaunos Therapeutics USD 921K 153K Sep/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Bayer EUR 32.58B 3.63B Dec/2025
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Cipla INR 62.97B 8.13B Sep/2025
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.57M 2.29M Dec/2025
CSL USD 4.61B 207M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Grifols EUR 2.37B 156.97M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
J&J USD 54.13B 3.26B Dec/2025
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Novartis USD 27.28B 4.72B Dec/2025
Omeros USD 85.5M 2.28M Jun/2025
Pfizer USD 36.6B 1.13B Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Tectonic Therapeutic USD 9.67M 293K Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025